The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Real-world outcomes of durvalumab ± tremelimumab in uHCC
Ciro Celsa, MD, PhD, University of Palermo, Palermo, Italy, discusses results from the DT-REAL study of durvalumab with or without tremelimumab in unresectable hepatocellular carcinoma (uHCC) according to HIMALAYA (NCT03298451) eligibility criteria. Patients who met trial criteria experienced longer survival and improved outcomes compared with those outside the criteria, with response and disease control rates consistent with previous data. Safety findings showed manageable toxicity, with most adverse events low grade. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The DT-REAL study is a multi-center study aiming to assess the safety and effectiveness of Durvalumab plus Tremelimumab for unresectable HCC. In this analysis we enrolled about 233 patients with unresectable HCC and we, across different centers in all the world, and we focused our analysis in comparing the outcomes according to key inclusion criteria of the HIMALAYA trial...
The DT-REAL study is a multi-center study aiming to assess the safety and effectiveness of Durvalumab plus Tremelimumab for unresectable HCC. In this analysis we enrolled about 233 patients with unresectable HCC and we, across different centers in all the world, and we focused our analysis in comparing the outcomes according to key inclusion criteria of the HIMALAYA trial. So we stratified the population in HIMALAYA in patients that are patients treated in first-line setting with Child-Pugh class with a performance status of 0 or 1 and without BCLC portal invasion versus HIMALAYA out patients. And basically we observed that patients classified as HIMALAYA in, so strictly fitting the main inclusion criteria of the HIMALAYA trial, displayed a significantly better outcome in terms especially of overall survival and also in terms of objective response rate. And from the point of view of the safety, both HIMALAYA in and HIMALAYA out patients show a good safety profile in absence of unexpected adverse events compared to the HIMALAYA trial results.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
